- Home
- DMAC vs MAV Comparison
DMAC vs MAV Comparison
Compare DMAC & MAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MAV
- Stock Information
- Founded
- DMAC 2000
- MAV 2003
- Country
- DMAC United States
- MAV United States
- Employees
- DMAC N/A
- MAV N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MAV Finance Companies
- Sector
- DMAC Health Care
- MAV Finance
- Exchange
- DMAC Nasdaq
- MAV Nasdaq
- Market Cap
- DMAC 158.1M
- MAV 184.1M
- IPO Year
- DMAC N/A
- MAV N/A
- Fundamental
- Price
- DMAC $4.11
- MAV $8.29
- Analyst Decision
- DMAC Strong Buy
- MAV
- Analyst Count
- DMAC 2
- MAV 0
- Target Price
- DMAC $8.00
- MAV N/A
- AVG Volume (30 Days)
- DMAC 102.4K
- MAV 66.2K
- Earning Date
- DMAC 05-13-2025
- MAV 01-01-0001
- Dividend Yield
- DMAC N/A
- MAV 4.30%
- EPS Growth
- DMAC N/A
- MAV N/A
- EPS
- DMAC N/A
- MAV N/A
- Revenue
- DMAC N/A
- MAV N/A
- Revenue This Year
- DMAC N/A
- MAV N/A
- Revenue Next Year
- DMAC N/A
- MAV N/A
- P/E Ratio
- DMAC N/A
- MAV N/A
- Revenue Growth
- DMAC N/A
- MAV N/A
- 52 Week Low
- DMAC $2.14
- MAV $6.37
- 52 Week High
- DMAC $6.82
- MAV $8.34
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- MAV 53.35
- Support Level
- DMAC $3.92
- MAV $8.14
- Resistance Level
- DMAC $4.33
- MAV $8.39
- Average True Range (ATR)
- DMAC 0.29
- MAV 0.09
- MACD
- DMAC 0.02
- MAV -0.01
- Stochastic Oscillator
- DMAC 56.79
- MAV 38.46
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MAV Pioneer Municipal High Income Advantage Fund Inc.
Pioneer Muni High Income Advantage Tr is a closed-end fund designed to pursue high current income exempt from regular federal income tax and as a secondary objective to seek capital appreciation. It predominantly invests in debt securities and other obligations issued by or on behalf of states, territories, and possessions of the United States and the District of Columbia and their political subdivisions, agencies, and instrumentalities, the interest on which is exempt from regular federal income tax.